How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

502,070 results for

(respiratory or pulmonary or lung or asthma or asthmatic or breathing)


Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Masks for Prevention of COVID-19 in Community and Healthcare Settings: A Living Rapid Review Full Text available with Trip Pro

of this review. Please send any comments or unpublished studies to . Rapid Review Journal Citation Chou R, Dana T, Jungbauer R, et al. Masks for prevention of respiratory virus infections, including SARS-CoV-2, in health care and community settings. A living rapid review. Ann Intern Med. 24 June 2020. [Epub ahead of print]. doi:10.7326/M20-3213. Rapid Review Citation Suggested citation: Chou R, Dana T, Jungbauer R, Weeks C, McDonagh M. Masks for Prevention of COVID-19 in Community and Healthcare Settings

2020 Effective Health Care Program (AHRQ)

182. Resumption of pulmonary function testing during the post-peak phase of the COVID-19 Pandemic - a position statement from the Canadian Thoracic Society and the Canadian Society of Respiratory Therapists

Resumption of pulmonary function testing during the post-peak phase of the COVID-19 Pandemic - a position statement from the Canadian Thoracic Society and the Canadian Society of Respiratory Therapists 1 ‘In Press’. Submitted for publication in the CJRCCSM on July 12, 2020 Resumption of Pulmonary Function Testing during the Post-Peak Phase of the COVID-19 Pandemic A Position Statement from the Canadian Thoracic Society and the Canadian Society of Respiratory Therapists Sanja Stanojevic (...) the Canadian Thoracic Society website ( or Canadian Society of Respiratory Therapists website ( for updates. The Canadian Association of Cardio- Pulmonary Technologists endorses this position statement. Pulmonary function tests (PFTs) are important for the diagnosis, management and monitoring of disease and there is an urgent need to safely resume services. Patients cannot wear a mask during the test and physical distancing of two

2020 CPG Infobase

183. Novel Coronavirus 2019 (COVID-19)

related to its effect on pregnant women and infants, and there currently are no recommendations specific to pregnant women regarding the evaluation or management of COVID-19. Currently available data on COVID-19 does not indicate that pregnant women are at increased risk. However, pregnant women are known to be at greater risk of severe morbidity and mortality from other respiratory infections such as influenza and SARS-CoV. As such, pregnant women should be considered an at-risk population for COVID (...) have tested positive for COVID-19 . While travel history is always an essential component of medical history intake, obstetrician–gynecologists and other health care practitioners should be vigilant in obtaining a detailed travel history as well as a history of exposure to people with symptoms of COVID-19 for all patients, including pregnant women presenting with fever or acute respiratory illness and should follow the and guidance for . Of note, health care practitioners should immediately notify

2020 American College of Obstetricians and Gynecologists

184. Chronic Cough Due to Stable Chronic Bronchitis: CHEST Expert Panel Report

of the data, or the preparation of the manuscript. Additional information: The e-Appendix can be found in the Supplemental Materials section of the online article. CHEST Expert Panel Collaborator, Mark Rosen, MD, FCCP, died July 2, 2019. References Q35 1. American Thoracic Society. Chronic bronchitis, asthma and pulmonary emphysema: a statement by the Committee on Diagnostic Standards for Nontuberculous Respiratory Diseases. Am Rev Respir Dis. 1962;85:762-768. 2. US Department of Health Education (...) pulmonary disease and its relationship with tobacco smoking and environmental tobacco smoke exposure. Indian J Chest Dis Allied Sci. 2006;48(1):23-29. 24. Kim V, Zhao H, Boriek AM, et al. Persistent and newly developed chronic bronchitis are associated with worse outcomes in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2016;13(7): 1016-1025. 25. Krzyzanowski M, Jedrychowski W. Occupational exposure and incidence of chronic respiratory symptoms among residents of Cracow followed for 13 years

2020 American College of Chest Physicians

185. Covid-19: Drug vignettes: Tocilizumab Full Text available with Trip Pro

4-weekly intravenous administration. Contraindications and warnings in licensed use Serious and sometimes fatal infections have been reported. The manufacturer therefore recommends that treatment should not be started during an active severe infection, or with conditions that can predispose to infections (e.g. diverticular disease, diabetes mellitus, interstitial lung disease). It is not clear how these restrictions would affect its use in acute infection with SARS-CoV-2. Tocilizumab can also (...) below 100 × 10 12 /L. They advise withholding treatment if the neutrophil count falls below 0.5 × 10 9 /L or the platelet count below 50 × 10 12 /L. They also advise caution in starting treatment in patients with liver transaminase activities more than 1.5 times the upper limit of normal and withholding treatment if transaminase activity rises above 3–5 times the upper limit of normal. Very common adverse effects (more than 1 in 10 people affected) include: Upper respiratory tract infections

2020 Oxford COVID-19 Evidence Service

186. COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19

that no evidence from published scientific studies was found to determine whether acute use of NSAIDs is related to increased risk of developing COVID-19 or increased risk of a more severe illness. The available evidence suggests that, although the anti-inflammatory effects of NSAIDs reduce acute symptoms (such as fever), they may either have no effect on, or worsen, long-term outcomes, possibly by masking symptoms of worsening acute respiratory tract infection. Further evidence is needed to confirm (...) , or if acute use of NSAIDs can lead to an increased risk of developing more severe symptoms of COVID-19. Therefore, with the agreement of NHS England, indirect evidence relating to the acute use of NSAIDs for other acute respiratory tract infections was summarised. Formal searches and critical appraisal were not conducted for this extension to the original question. COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES23) ©

2020 NICE COVID-19 rapid evidence summary

188. Preterm labour and birth

• Minimum 4 hourly or more frequently as clinically indicated • Serum monitoring not usually required if renal function normal o Therapeutic serum magnesium levels are 1.7–3.5 mmol/L Discontinuation and urgent medical review • Respiratory rate less than 12 breaths/minute or more than 4 breaths/minute below baseline • Diastolic BP decreases more than 15 mmHg below baseline • Absent deep tendon reflexes • Urine output less than 25 mL/hour or less than 100 mL over 4 hours • Magnesium serum levels greater (...) corticosteroids Table 12. Antenatal corticosteroids Aspect Consideration Context • Antenatal corticosteroids are associated with a significant reduction in rates of neonatal death, respiratory distress syndrome and intraventricular haemorrhage (IVH) 49,50 • Antenatal corticosteroid use is also associated with a reduction in necrotising enterocolitis, respiratory support, intensive care admissions and systemic infections in the first 48 hours of life compared with no treatment or treatment with placebo 49,50

2020 Queensland Health

189. Managing common infections: guidance for primary care

Managing common infections: guidance for primary care Managing common infections: guidance for primary care - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Managing common infections: guidance for primary care Guidance for managing common infections, including upper and lower respiratory, and urinary tract infections. Published 5 August 2010 Last updated 2 August 2019 — From: and Documents https (...) Removed Chronic Obstructive Pulmonary Disease (COPD) guidance from documents. 31 October 2018 Updated guidance based on user feedback and added Lyme's disease. Replaced guidance on UTI, acute sore throat, acute otitis media and sinusitis with NICE guidelines and joint table now published on NICE website. 5 December 2017 Updated guidance following minor review in November 2017 7 September 2017 Updated guidance and summary tables after consultation. 8 August 2017 Added link to a new draft version

2020 Public Health England

191. Localised Colon Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

whether the patient should be referred for primary tumour resection or, in the presence of unresectable distant metastases, systemic therapy. Approximately 20% of newly diagnosed colon cancers have synchronous metastasis, the most frequently involved organ being the liver (17%), followed by peritoneum (5%), lung (5%) and lymph nodes (3%) [24]. CT of the thoracic, abdominal and pelvic cavities with intravenous contrast administration is the preferred radiological method for the evaluation (...) significant improvements in survival, though all studies considering liver imaging also 24 included blood CEA monitoring [92]. CT scan including optimal liver assessment has been shown to be more sensitive than ultrasonography (0.67 compared with 0.43) for liver relapse follow-up and, in addition, can detect chest recurrences. On the other hand, liver MRI may be an alternative when a CT scan has shown confusing liver lesions [93]. Regarding the timing and duration of follow-up, protocols need

2020 European Society for Medical Oncology

192. Trastuzumab (Zercepac) - breast cancer, gastric cancer

, reactions related to the infusion, reduced levels of blood cells (especially white blood cells), infections and lung problems. Zercepac can cause cardiotoxicity (harm to the heart), including heart failure (when the heart does not work as well as it should). Care should be taken if it is given to patients who already have heart problems or high blood pressure, and all patients need to be monitored during and after treatment to check their heart. Zercepac must not be used in people who are hypersensitive (...) (allergic) to trastuzumab, mouse proteins or to any of the other ingredients. It must not be used in patients whose advanced cancer causes serious breathing problems even when resting, or who need oxygen therapy. For the full list of side effects and restrictions, see the package leaflet. Zercepac (trastuzumab) EMA/296174/2020 Page 3/3 Why is Zercepac authorised in the EU? The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Zercepac has a highly

2020 European Medicines Agency - EPARs

193. Lefamulin (Xenleta) - community-acquired pneumonia

and why it is authorised in the EU What is Xenleta and what is it used for? Xenleta is an antibiotic used in adults to treat community-acquired pneumonia (a lung infection caught outside of hospital) when other antibiotic medicines are not suitable or do not work. Xenleta contains the active substance lefamulin. How is Xenleta used? Xenleta can only be obtained with a prescription, and official guidelines on the use of antibiotics should be considered by the prescribing doctor. Xenleta can be given

2020 European Medicines Agency - EPARs

194. Apixaban - venous thromboembolism, DVT and stroke

Accord and why it is authorised in the EU What is Apixaban Accord and what is it used for? Apixaban Accord is a medicine used to prevent venous thromboembolism (blood clots in the veins) in adults following a hip or knee replacement operation. It is also used in adults to treat deep vein thrombosis (blood clot in a deep vein, usually in the leg) and pulmonary embolism (clot in a blood vessel supplying the lungs), and to prevent their reoccurrence. Additionally, Apixaban Accord is used to prevent (...) on age, bodyweight and level of creatinine in the blood. For more information about using Apixaban Accord, see the package leaflet or contact your doctor or pharmacist. How does Apixaban Accord work? Patients undergoing hip or knee replacement surgery, who have had a recent trauma, or are confined to bed are at a high risk of blood clots forming in the veins, which can be dangerous and even fatal if these clots move to another part of the body such as the lungs. Similarly, patients with atrial

2020 European Medicines Agency - EPARs

196. COVID-19 Rail Protocol: Recommendations for safe resumption of railway services in Europe

for cross-border contact tracing, which should be developed in consultation with the relevant authorities in the countries operating international trains (see section 5.1). b. Training Training of station, train, and all railway employees is needed on the adopted measures and applied procedures. This should include information on how COVID-19 is transmitted, physical distancing measures, hand and respiratory hygiene, the appropriate use of the recommended personal protective equipment (PPE (...) travellers and migrant or seasonal workers. However, virus re-introduction would not necessarily lead to widespread community transmission if strong surveillance, extensive testing and robust contact tracing measures are in place, together with ongoing risk communication about the importance of staying at home if travellers or staff have symptoms, physical distancing, hand and respiratory hygiene. h. Balancing risk factors vs. practical implementation Preventive measures should be implemented

2020 European Centre for Disease Prevention and Control - Technical Guidance

197. CCS/CTS Position Statement on Pulmonary Hypertension Full Text available with Trip Pro

Thoracic Society clinical practice guideline update. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 2019; 3 : 177-198 Figure 1 An algorithm for the work-up of pulmonary hypertension (PH). ABG, arterial blood gas; CHD, congenital heart disease; CT, computed tomography; CTD, connective tissue disease; CTEPH, chronic thromboembolic pulmonary hypertension; DLCO, diffusion capacity of the lung for carbon monoxide; ECG, electrocardiogram; HR-CT, high-resolution computed tomography; mPAP (...) (CCS)/Canadian Thoracic Society position statement in 2005. Globally, PH has an estimated prevalence of 1%, increasing to 10% in those aged 65 years and older, most commonly due to left heart or lung disease. Hoeper M.M. Humbert M. Souza R. et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016; 4 : 306-322 Consequently, the phenotype of PH patients has changed, now being older with multiple comorbidities. A PH diagnosis confers a sevenfold increase in standardized mortality rates

2020 Canadian Cardiovascular Society

198. 2020 CCS/CHRS Position Statement on the Management of Ventricular Tachycardia and Fibrillation in Patients with Structural Heart Disease

by 20%-30% when starting amiodarone and monitor INR frequently Laboratory: • Liver enzymes and thyroid function (TSH) baseline and every 6 months ECG: • Baseline Chest x-ray: • Baseline if preexisting lung disease and with symptoms Pulmonary function testing • Baseline for those with preexisting lung disease Ophthalmologic evaluation: • Baseline if existing visual impairment and with symptoms Skin (photosensitivity) Ataxia/tremor Visual changes Nausea or diarrhea (particularly with loading dose (...) . et al. Successful ventricular tachycardia ablation in patients with electrical storm reduces recurrences and improves survival. Heart Rhythm. 2018; 15 : 48-55 For recurrent polymorphic VT or VF in the absence of acute ischemia, administration of I.V. magnesium can be considered. Treatment directed at acute heart failure should also be considered, because this can precipitate VT/VF. Refractory patients might benefit from thoracic epidural anaesthesia or percutaneous cardiac sympathetic denervation

2020 Canadian Cardiovascular Society

199. What is known about the incubation period for COVID-19?

onset. European Respiratory Journal. Epub ahead of print. Median incubation period from exposure to onset of symptoms was 5.0 days (IQR 2.0-10.0). Cheng, H.Y., Jian, S.-W., Liu, D.P., Ng, T.C., Huang, W.T., & Lin, H.H. (2020). Contact Tracing Assessment of COVID- 19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset. JAMA Internal Medicine. Epub ahead of print. May 1, 2020 Case series Taiwan No index event, Jan 15- Mar 18 22 Close contacts (...) , S.F., Su, Y.Y., Li, Z.Y., Liu, W., Yu, F., Ge, S.X., Zou, Q.D., Yuan, Q., Lin, S., Hong, C.M., Yao, X.Y., Zhang, X.J., Wu, D.H., Zhou, G.L., Hou, W.H., Li, T.T., Zhang, Y.L., … Chen, Y. (2020). Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset. European Respiratory Journal. Epub ahead of print. McAloon, C. G., Collins, A., Hunt, K., Barber, A., Byrne, A., Butler, F., Casey, M., Griffin, J. M., Lane, E., McEvoy, D., Wall, P., Green, M. J., O’Grady, L., & More, S

2020 COVID-19 Rapid Evidence Service

200. Covid-19: What is known about how long the virus can survive with potential for infection on surfaces?

., Okamoto, K., … Wakita, T. (2020). Environmental sampling for severe acute respiratory syndrome coronavirus 2 during COVID-19 outbreak in the Diamond Princess cruise ship. The Journal of Infectious Diseases. Epub ahead of print. Jul 21, 2020 Prevalence Cruise ship Surface samples from vacant cabins of those with confirmed COVID-19 cases, cabins with no confirmed cases, and common areas. Reverse transcription polymerase chain reaction (RT-PCR) used to detect presence of SARS- CoV-2 RNA. Samples (...) respiratory syndrome coronavirus 2 (SARS-CoV-2) from medical equipment in long-term care facilities undergoing COVID-19 outbreaks. American Journal of Infection Control. Epub ahead of print. Jul 10, 2020 Prevalence 3 long-term care facilities with confirmed outbreaks Surface samples from high-touch surfaces, communal sites, and mobile medical equipment. Patient rooms and bathrooms were excluded. Canada RT-PCR Cleaning protocols not reported. 6 of 89 (6.7%) samples tested positive. Positive samples were

2020 COVID-19 Rapid Evidence Service

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>